Small molecule · developed by Bausch Health Americas
Rifaximin SSD is a solid soluble dispersion formulation of rifaximin, studied as an immediate-release twice-daily product.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05071716 | Phase 3 | Hepatic Encephalopathy | Completed | BHC |
| NCT06718686 | Phase 1/2 | Dementia Alzheimer Type | Recruiting | BHC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dementia Alzheimer TypeDementia Associated With Cerebrovascular DiseaseHepatic Encephalopathy
Updated Nov 1, 2026. Something wrong or missing? Report it on the BHC page.
See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BHC catalysts and pipeline →